Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Should You Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) shares gapped up prior to trading on Tuesday . The stock had previously closed at $20.75, but opened at $21.7899. Chugai Pharmaceutical shares last traded at $20.8345, with a volume of 12,930 shares trading hands.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CHGCY. The Goldman Sachs Group raised Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. Zacks Research upgraded Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. Nomura raised Chugai Pharmaceutical to a “hold” rating in a research note on Tuesday, September 1st. Finally, UBS Group lowered shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Performance

The company has a fifty day moving average price of $21.74 and a two-hundred day moving average price of $24.49. The company has a market cap of $67.61 billion, a P/E ratio of 22.33 and a beta of 0.59.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Friday, July 24th. The company reported $0.22 EPS for the quarter. The firm had revenue of $2.14 billion during the quarter, compared to analysts’ expectations of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%. Research analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 EPS for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs.

Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer.